Skip to content

Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19

Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04560608
Acronym
GERIA-COVID
Enrollment
700
Registered
2020-09-23
Start date
2020-03-15
Completion date
2022-12-31
Last updated
2021-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

elderly, coronavirus disease

Brief summary

Statement : * The emerging Coronavirus 2019 (COVID-19) disease, linked to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pathogen, has been spreading worldwide since December 2019, affecting millions of people and causing hundreds of thousands of deaths, particularly among the elderly. * The first epidemiological evidence available reveals a different expression of the disease in the elderly, associated with a high risk of delayed diagnosis and implementation of protective measures and a particularly high morbidity and mortality, especially among the frailest. * To date, there is no effective model for predicting the severity of COVID-19 in an individual. The investigators hypothesize that there are specificities of COVID-19 in the elderly, both etiological, diagnostic and prognostic, all of which are not yet known and understood.

Interventions

None listed

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hospitalization in the Geriatric unit of the University Hospital (UH) of Angers from 15/03/2020 and until the closure of the COVID-19 geriatric sector

Exclusion criteria

* Opposition to the use of the information collected for research purposes.

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of COVID-19baselineRecovery of the diagnosis method (PCR or thoracic scan)
Length of hospitalizationat the 3-month follow-up
Medical history and co-morbiditiesbaselinelisting of medical history and co-morbidities data provided by the physician and the family during hospitalization
The physical examination data, and reports of relevant investigations data provided by the physician and the family during hospitalizationbaselineThe demographic characteristics are age, sex, marital status, place of life, career, presence of un/formal assistance, …
Electrocardiography QT Intervalbaselineall electrocardiograms performed during hospitalization
Number of different therapeutic classesbaselineNumber of different therapeutic classes taken per day.
Comprehensive Geriatric Assessment (CGA)baselineComprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging. CGA is based on the premise that a systematic evaluation of frail older persons by a team of health professionals may identify a variety of treatable health problems and lead to better health outcomes.
Biological parametersbaselineCharacterization of the COVID-19 impact on the biological parameters evaluated by blood test.
Medical imaging resultsbaselineAssessment of lesion extension (percent) with medical imaging results (thoracic scan)
Number of death from any causeat the 3-month follow-up
Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-upat the 3-month follow-upThe demographic characteristics are age, sex, marital status, place of life, career, presence of un/formal assistance, …

Countries

France

Contacts

Primary ContactCédric ANNWEILER, MD, PhD
cedric.annweiler@chu-angers.fr02 41 35 47 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026